Search

Displaying results 9081 - 9090 of 9613 in total

Drug
Gavestinel
go.drugbank.com/drugs/DB06741
Experimental
Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).
Drug
Phosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082
Experimental
It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of adenylate cyclase.
Drug
(1R,2S)-2-Phenylcyclopropanaminium
go.drugbank.com/drugs/DB02665
Experimental
It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Drug
AdimrSC-2f
go.drugbank.com/drugs/DB16436
Investigational
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Drug
RGX-181
go.drugbank.com/drugs/DB17942
Experimental
Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072]
Drug
NC-6300
go.drugbank.com/drugs/DB17341
Experimental
NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.
Drug
YKP-1358
go.drugbank.com/drugs/DB06109
Experimental
YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Drug
Zibrofusidic acid
go.drugbank.com/drugs/DB20799
Investigational
Zibrofusidic acid has a monoisotopic molecular weight of 594.26 Da.
Drug
Evixapodlin
go.drugbank.com/drugs/DB21520
Investigational
Evixapodlin has a monoisotopic molecular weight of 690.22 Da.
Drug
PTI-801
go.drugbank.com/drugs/DB05300
Investigational
It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.